Navigation Links
Ovarian Cancer Breakthrough Heralds New Era of Treatment
Date:6/10/2009

Scientists identify cause of deadly tumors and predict life-saving developments could follow

WEDNESDAY, June 10 (HealthDay News) -- Canadian researchers have zeroed in on the cause of a deadly type of ovarian cancer, a finding that could lead to successful treatment of the rare granulosa cell tumors.

The culprit is a single mutation out of 3 billion nucleotide pairs that make up the genetic code of the tumor. The mutation is present in every granulosa cell tumor, a rare and often untreatable form of ovarian cancer that affects about 5 percent of ovarian cancer patients, according to a study that appears in the June 10 online issue of the New England Journal of Medicine.

The discovery, made using state-of-the-art gene-sequencing technologies, may mark the beginning of a new era of cancer genomics, in which the complete genetic sequence of cancers and the mutations that cause them can be identified, researchers said.

For women with granulosa cell tumors, the precise identification of the mutation may help in developing new, badly needed treatments.

"This is really a two-fold discovery," said lead study author Dr. David Hunstman, a genetic pathologist at the BC Cancer Agency and Vancouver General Hospital and an associate professor at the University of British Columbia.

"It clearly shows the power of the new generation of DNA sequencing technologies to impact clinical medicine, and for those of us in the area of ovarian cancer research and care, by identifying the singular mutation that causes granulosa cell tumors, we can now more easily identify them and develop new ways to treat them," he added in a university news release.

In the study, researchers decoded four granulosa cell tumors using "next generation" sequencing machines that decode billions of nucleotides at rapid speed and new computer techniques to quickly assemble the data.

While most types of cancer, including ovarian cancers, have a broad range of genetic abnormalities, researchers found a mutation in a single nucleotide in the FOXL2 gene in every sample.

The research team further validated the findings by examining additional tumor samples from across Canada and around the world.

In the past, analyzing the sequence of a tumor was a laborious process, and most studies could only look at one or only a few of the 20,000 genes in the human genome. The new sequencing technologies allow scientists to look at all at once.

"This task would have been unfathomable in terms of both cost and complexity even two years ago," said Dr. Marco Marra, director of the BC Cancer Agency's Genome Sciences Center.

Researchers chose granulosa cell tumors because, unlike other cancers, they are "clinically homogenous," Huntsman said.

"This cancer is unique," said Dr. Dianne Miller, a gynecologic oncologist at BC Cancer Agency and Vancouver General Hospital. "For patients with this tumor type, it means they should all have the same response to the same treatment. And now that we have this pathway, we can look for existing cancer drugs that might work on this particular gene mutation to make the cancer disappear."

Researchers plan to study other rare tumor types using a similar method.

More information

The American Cancer Society has more on ovarian cancer.



-- Jennifer Thomas



SOURCE: University of British Columbia, news release, June 10, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Cranberry Could Juice Up Ovarian Cancer Treatment
2. New Ovarian Cancer Drug Trial Under Way
3. Pelvic Exams Can Help Spot Ovarian Cancer
4. Study fuels debate over whether exercise and body size influence ovarian cancer risk
5. Experimental drug boosts survival in recurrent ovarian cancer
6. New Ovarian Cancer Biomarker Research Act Introduced
7. Common Early-Warning Symptoms of Ovarian Cancer Identified in CDC/Thomson Healthcare Study
8. More Fiber, Less Fat Help Prevent Ovarian Cancer
9. Media availability: low-fat dietary pattern may lower risk of ovarian cancer
10. The Silent Killer, Ovarian Cancer on Your Cancer Today (TM)
11. Society of Gynecologic Oncologists Provides Guidelines for Offering Genetic Risk Assessment to Women With a Personal or Family History of Breast, Ovarian, Uterine or Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Ovarian Cancer Breakthrough Heralds New Era of Treatment 
(Date:12/7/2016)... ... December 07, 2016 , ... AlignLife clinics nationwide are giving back to ... fortunate enough to receive bountiful gifts wrapped tightly under a Christmas Tree. AlignLife ... children of the world. , In exchange for generous donations, customers will receive a ...
(Date:12/7/2016)... ... December 07, 2016 , ... Facial plastic surgeon, Dr. John D. ... donating a portion of proceeds to two local organizations: North Chicago Animal Control and ... Friends is a team of authorized and trained volunteers who support rescued animals ...
(Date:12/7/2016)... ... ... "ProBrand Flip allows FCPX editors to create unique logo reveals which can ... Film Studios. , ProBrand Flip includes 30 flip book reveal animations. Easily reveal any ... variety of flip book animations. In Addition, users can modify each preset to fit ...
(Date:12/7/2016)... ... ... “Tomorrow Trump Goes To Washington”: a brief but engaging illustration depicting the ... “Tomorrow Trump Goes To Washington” is the creation of published author, Nancy Engestrom, a ... Nancy attributes her patriotic nature to her WWII veteran father. She says, “I ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... honored to present at the International Probiotic Association’s Washington DC workshop on November ... regulators to engage in dialog regarding probiotic dietary supplement regulations. , Dr. ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... Today, Stock-Callers.com presents four Biotech equities ... ), Anthera Pharmaceuticals Inc. (NASDAQ: ANTH ), ProNAi ... (NASDAQ: AVXS ). From its peak in July ... reach a level equal to what it saw at the ... for the year, it has still out-performed other market sectors, ...
(Date:12/6/2016)... , Dec. 6, 2016  Licenders is bringing their 100% all-natural ... location in Park Slope at 203 13 th Street was ... clientele. "Our goal is to ease parents, ... are designed to get children right back to class without skipping ... all natural and safe for the whole family," Licenders President ...
(Date:12/6/2016)... -- Diabetes & Obesity Drug Development Pipeline Review, 2016 ... is currently dominated by therapeutics indicated for type 1 ... and the majority of the pipeline, in terms of ... these indications. While products indicated for obesity do not ... large number of these products in the pipeline, with ...
Breaking Medicine Technology: